Core Viewpoint - The article discusses the advancements in GLP-1 drug development, particularly focusing on Eli Lilly's innovative drugs, Tirzepatide and Retatrutide, and their potential applications in treating various conditions, including MASLD [4][6]. Group 1: Clinical Trials and Research - Eli Lilly registered a Phase III clinical trial for Tirzepatide and Retatrutide targeting MASLD, aiming to enroll 4,500 patients, with preliminary results expected by 2030 [4]. - The trial will evaluate the efficacy and safety of Tirzepatide and Retatrutide in treating MASLD, with the primary observation endpoint being the MALO composite endpoint [4]. Group 2: Drug Development and Mechanism - Eli Lilly maintains a leading position in multi-target GLP-1 drug development, with Tirzepatide being the first GLP-1/GIP dual-target agonist and Retatrutide being the first triple-target agonist acting on GLP-1/GIP/GCG [6]. - Retatrutide is currently involved in multiple Phase III studies, including those for obesity and type 2 diabetes, and the new MASLD trial expands its indication exploration [6]. - Additionally, Retatrutide is being evaluated for its potential efficacy in chronic kidney disease (CKD) [6].